Next Article in Journal
Nutraceuticals in Paediatric Patients with Dyslipidaemia
Next Article in Special Issue
Scientific Evidences of Calorie Restriction and Intermittent Fasting for Neuroprotection in Traumatic Brain Injury Animal Models: A Review of the Literature
Previous Article in Journal
An Update on Vitamin D Deficiency Status in Malaysia
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials

IFF Health and Biosciences, Danisco Sweeteners Oy, Sokeritehtaantie 20, 02460 Kantvik, Finland
*
Author to whom correspondence should be addressed.
Nutrients 2022, 14(3), 568; https://doi.org/10.3390/nu14030568
Submission received: 24 December 2021 / Revised: 24 January 2022 / Accepted: 26 January 2022 / Published: 27 January 2022
(This article belongs to the Special Issue Nutrition, Brain and Cognition)

Abstract

The microbiota–gut–brain axis is a bidirectional communication pathway that enables the gut microbiota to communicate with the brain through direct and indirect signaling pathways to influence brain physiology, function, and even behavior. Research has shown that probiotics can improve several aspects of health by changing the environment within the gut, and several lines of evidence now indicate a beneficial effect of probiotics on mental and brain health. Such evidence has prompted the arrival of a new term to the world of biotics research: psychobiotics, defined as any exogenous influence whose effect on mental health is bacterially mediated. Several taxonomic changes in the gut microbiota have been reported in neurodevelopmental disorders, mood disorders such as anxiety and depression, and neurodegenerative disorders such as Alzheimer’s disease. While clinical evidence supporting the role of the gut microbiota in mental and brain health, and indeed demonstrating the beneficial effects of probiotics is rapidly accumulating, most of the evidence to date has emerged from preclinical studies employing different animal models. The purpose of this review is to focus on the role of probiotics and the microbiota–gut–brain axis in relation to mood disorders and to review the current translational challenges from preclinical to clinical research.
Keywords: probiotic; gut microbiota; neurotransmitters; anxiety; depression probiotic; gut microbiota; neurotransmitters; anxiety; depression

Share and Cite

MDPI and ACS Style

Forssten, S.D.; Ouwehand, A.C.; Griffin, S.M.; Patterson, E. One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials. Nutrients 2022, 14, 568. https://doi.org/10.3390/nu14030568

AMA Style

Forssten SD, Ouwehand AC, Griffin SM, Patterson E. One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials. Nutrients. 2022; 14(3):568. https://doi.org/10.3390/nu14030568

Chicago/Turabian Style

Forssten, Sofia D., Arthur C. Ouwehand, Síle M. Griffin, and Elaine Patterson. 2022. "One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials" Nutrients 14, no. 3: 568. https://doi.org/10.3390/nu14030568

APA Style

Forssten, S. D., Ouwehand, A. C., Griffin, S. M., & Patterson, E. (2022). One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials. Nutrients, 14(3), 568. https://doi.org/10.3390/nu14030568

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop